Insights

Gathering insights about Akero…

Similar companies to Akero

Akero Tech Stack

Akero uses 8 technology products and services including WP Rocket, WordPress, Webpack, and more. Explore Akero's tech stack below.

WP Rocket
Caching
WordPress
Content Management System
Webpack
Development
Polyfill
Javascript Libraries
Workable
Recruitment Marketing
KnowBe4
Security
Onsen UI
Software Development
Apache HTTP Server
Web Servers

Media & News

Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO
Bourgeon Capital Management LLC acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 9,936 shares of the company's stock, valued at approximately $472,000. Other institutional investors and hedge funds
Jan 03, 2026 | www.defenseworld.net
Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO
Corient Private Wealth LLC acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,553 shares of the company's stock, valued at approximately $3,925,000. Corient Private Wealth
Dec 22, 2025 | www.defenseworld.net
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO
Alkeon Capital Management LLC increased its holdings in Akero Therapeutics, Inc. (NASDAQ: AKRO) by 19.3% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,850,934 shares of the company's stock after buying an additional 300,000 shares during the period. Alkeon Capital Management LLC owned 2.31%
Dec 13, 2025 | www.defenseworld.net
Novo Nordisk has completed its acquisition of Akero Therapeutics
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk's acquisition of Akero, announced on 9 October 2025, has been completed. With the completion of the transaction, Novo Nordisk has acquired all outstanding shares of common stock and common stock equivalents of Akero for 54 USD per share in cash (or aggregated value of 4.7 billion USD) and a non-transferable Contingent Value Right (“CVR”).
Dec 09, 2025 | www.globenewswire.com
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akero Therapeutics, Inc. (NasdaqGS: AKRO) to Novo Nordisk A/S. Under the terms of the proposed transaction, shareholders of Akero will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S.
Nov 20, 2025 | www.businesswire.com
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Radha Raghavan at rraghavan@bergermontague.com or (215) 875-4698, or CLICK HERE.
Nov 12, 2025 | www.prnewswire.com
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c) due to MASH
Nov 07, 2025 | www.globenewswire.com

Akero's Email Address Formats

Akero uses at least 1 format(s):

Akero Email Formats	Example	Percentage
First.Last@akerolabs.com	John.Doe@akerolabs.com	68%
FirstLast@akerolabs.com	JohnDoe@akerolabs.com	11%
First@akerolabs.com	John@akerolabs.com	10%
FirLast@akerolabs.com	JohDoe@akerolabs.com	11%

Frequently Asked Questions

Where is Akero's headquarters located?

Akero's main headquarters is located at 134 North 4th Street Second Floor New York, New York United States. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is Akero's stock symbol?

Akero is a publicly traded company; the company's stock symbol is AKRO.

What is Akero's official website and social media links?

Akero's official website is akerolabs.com and has social profiles on LinkedIn.

What is Akero's SIC code NAICS code?

Akero's SIC code is 7372 - Prepackaged Software NAICS code is 6113 - Colleges, Universities, and Professional Schools.

How many employees does Akero have currently?

As of May 2026, Akero has approximately 9 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Operating Officer: D. S.Head Of Sales: S. S.Client Services Manager: A. C.. Explore Akero's employee directory with LeadIQ.

What industry does Akero belong to?

Akero operates in the Higher Education industry.

What technology does Akero use?

Akero's tech stack includes WP RocketWordPressWebpackPolyfillWorkableKnowBe4Onsen UIApache HTTP Server.

What is Akero's email format?

Akero's email format typically follows the pattern of First.Last@akerolabs.com. Find more Akero email formats with LeadIQ.

When was Akero founded?

Akero was founded in 2019.

Akero

Q: What is Akero's official website and social media links?

Akero's official website is akerolabs.com. Akero has social profiles on LinkedIn.

Q: How many employees does Akero have currently?

Akero has approximately 9 employees.

Q: What technology does Akero use?

Akero's tech stack includes MySQL, AOS, Element UI, Mailgun, RSS.

Q: What is Akero's NAICS code?

Akero's NAICS code is 6113 (Colleges, Universities, and Professional Schools).

Higher EducationNew York, United States2-10 Employees

Seamlessly connect your digital marketing spend to your enrollment outcomes and visualize the whole student journey so you can increase enrollment and reduce costs.
Discover our top 3 products: 
- Campaigns:  AI powered student advertising with guaranteed results.
- Convert: Don't let your perfect students slip through your fingers with next gen forms and landing pages.
- Connect: Seamlessly intergrate with all major CRMS to get complete clarity on your recruitment funnel

Company Overview

Headquarters: 134 North 4th Street Second Floor New York, New York United States
Website: akerolabs.com
SIC Code: 7372 - Prepackaged Software
Stock Symbol: AKRO
NAICS Code: 6113 - Colleges, Universities, and Professional Schools
Founded: 2019
Employees: 2-10

Media & News

Funding & Financials

$1M
Akero's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
Akero's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Akero

Alterline

Jenzabar

Opendorse

Whiteboard CRM

Helix Education

Unibuddy

Adventus.io

BridgeU

Lanterna Education

QS

Akero Tech Stack

Media & News

Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO

Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO

Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO

Novo Nordisk has completed its acquisition of Akero Therapeutics

Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO

Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Akero's Email Address Formats

Frequently Asked Questions

Where is Akero's headquarters located?

What is Akero's stock symbol?

What is Akero's official website and social media links?

What is Akero's SIC code NAICS code?

How many employees does Akero have currently?

What industry does Akero belong to?

What technology does Akero use?

What is Akero's email format?

When was Akero founded?

Akero

Company Overview

Media & News

Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO

Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO

Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?